Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947779978> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W2947779978 abstract "e12037 Background: Disease-free survival (DFS) in patients with EBC has improved over time. Trials of systemic agents for adj rx of HER2+ BC, including chemotherapies (CT), endocrine, and HER2-targeted agents have reported improved DFS. This review is a high-level overview describing DFS improvements in adj rx HER2+ BC. Methods: Therapeutic agents listed in NCCN guidelines for adj rx HER2+ BC were evaluated for relative and absolute improvements in DFS. Information was derived from US product labels and publications. Hazard ratios, 95% CI, p-values, and DFS differences at 2 and 5 years (if available) are reported. Results: At 2−3 years, adj rx of HER2+ BC with CT and HER2 treatments reported DFS improvements of 4−5% and 0.9−11.3%, respectively. For hormone receptor positive (HR+) BC, unselected by HER2 status, extended adj letrozole had a 1.9% DFS improvement at 2 years; in HR+ HER2+ BC, extended adj neratinib had 4.5% DFS at 2 years. Conclusions: Relative and absolute improvements in DFS in the adj rx BC setting have been largely incremental and cumulative. Absolute improvements in DFS were 0.9−11.3% with CT, HER2 agents, and AIs. In the subset of HR+ / HER2-positive patients, neratinib showed higher DFS improvement compared to non-steroidal AIs. Similar hazard ratios did not always correspond to similar DFS improvements, possibly reflecting differences in baseline risks in the study populations. [Table: see text]" @default.
- W2947779978 created "2019-06-07" @default.
- W2947779978 creator A5014578175 @default.
- W2947779978 creator A5030497065 @default.
- W2947779978 creator A5032187510 @default.
- W2947779978 creator A5036760135 @default.
- W2947779978 creator A5063718631 @default.
- W2947779978 creator A5072015843 @default.
- W2947779978 date "2019-05-20" @default.
- W2947779978 modified "2023-09-27" @default.
- W2947779978 title "Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC)." @default.
- W2947779978 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12037" @default.
- W2947779978 hasPublicationYear "2019" @default.
- W2947779978 type Work @default.
- W2947779978 sameAs 2947779978 @default.
- W2947779978 citedByCount "0" @default.
- W2947779978 crossrefType "journal-article" @default.
- W2947779978 hasAuthorship W2947779978A5014578175 @default.
- W2947779978 hasAuthorship W2947779978A5030497065 @default.
- W2947779978 hasAuthorship W2947779978A5032187510 @default.
- W2947779978 hasAuthorship W2947779978A5036760135 @default.
- W2947779978 hasAuthorship W2947779978A5063718631 @default.
- W2947779978 hasAuthorship W2947779978A5072015843 @default.
- W2947779978 hasConcept C121608353 @default.
- W2947779978 hasConcept C126322002 @default.
- W2947779978 hasConcept C143998085 @default.
- W2947779978 hasConcept C2777863537 @default.
- W2947779978 hasConcept C2777982462 @default.
- W2947779978 hasConcept C2779786085 @default.
- W2947779978 hasConcept C2780035454 @default.
- W2947779978 hasConcept C530470458 @default.
- W2947779978 hasConcept C71924100 @default.
- W2947779978 hasConcept C98274493 @default.
- W2947779978 hasConceptScore W2947779978C121608353 @default.
- W2947779978 hasConceptScore W2947779978C126322002 @default.
- W2947779978 hasConceptScore W2947779978C143998085 @default.
- W2947779978 hasConceptScore W2947779978C2777863537 @default.
- W2947779978 hasConceptScore W2947779978C2777982462 @default.
- W2947779978 hasConceptScore W2947779978C2779786085 @default.
- W2947779978 hasConceptScore W2947779978C2780035454 @default.
- W2947779978 hasConceptScore W2947779978C530470458 @default.
- W2947779978 hasConceptScore W2947779978C71924100 @default.
- W2947779978 hasConceptScore W2947779978C98274493 @default.
- W2947779978 hasLocation W29477799781 @default.
- W2947779978 hasOpenAccess W2947779978 @default.
- W2947779978 hasPrimaryLocation W29477799781 @default.
- W2947779978 isParatext "false" @default.
- W2947779978 isRetracted "false" @default.
- W2947779978 magId "2947779978" @default.
- W2947779978 workType "article" @default.